Recent research identifies the oxytocin receptor (OXTR) as a critical driver of liver cancer via Hippo/YAP signaling. The FDA-approved tocolytic drug Atosiban shows promise in blocking this pathway, offering new therapeutic avenues in hepatocellular carcinoma management.